In the Phase III ENVISION trial, Zusduri achieved a 24-month duration of response rate of 72.2% among patients with a ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

While DCTs failed to transform clinical research, artificial intelligence (AI)-powered study approaches are now fulfilling their promise within the non-interventional research space. Unified, digital ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, shares key ...

In the Phase III TRIUMpH program, tegoprazan met primary endpoints and outperformed lansoprazole in maintaining healing of ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, outlines the key ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...